ACT Brief: Ultra-Compressed CNPV Review Timelines, New IgAN Therapy Approval, and Smarter Clinical Reference Data Strategies

This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.

A new ACT Q&A takes a deep look at how the FDA’s Commissioner’s National Priority Voucher Program is redefining what sponsors and CROs must deliver to meet a one-to-two-month review cycle. Veristat’s John Kirk explains why compressed timelines require manufacturing readiness earlier than a standard NDA, real-time data quality, and tightly integrated workflows across biostats, regulatory, medical writing, and site operations. He emphasizes that enhanced FDA communication under the program mirrors breakthrough therapy expectations—driving more iterative engagement, faster turnaround on queries, and greater cross-functional coordination from the earliest phases of development.

In regulatory news, the FDA has granted accelerated approval to Otsuka’s Voyxact, the first APRIL-targeting therapy for adults with primary immunoglobulin A nephropathy (IgAN). Backed by Phase III VISIONARY results showing a 51% reduction in proteinuria at nine months, the approval provides a new targeted option for patients at risk of disease progression. The confirmatory portion of the trial, evaluating eGFR slope at 24 months, is expected in 2026 and will determine long-term impact on kidney function.

And at the 2025 Veeva R&D and Quality Summit, Henry Galio outlined how sponsors and CROs are struggling with fragmented, internally maintained clinical reference data—a model that creates hidden costs, duplication, and operational drag. He described how shifting to an integrated reference data solution can streamline workflows, improve alignment across functions, and reduce the maintenance burden that weighs heavily on both large biopharmas and their partners. Galio highlighted that a unified, ecosystem-wide data strategy is becoming essential as trials grow more complex and data volumes expand.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.